BELL.L

Belluscura Plc
Belluscura PLC - Result of General Meeting
27th August 2024, 13:17
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8597B
Belluscura PLC
27 August 2024
 

27 August 2024

 

Belluscura plc 

("Belluscura" or the "Company")

 

Result of General Meeting

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly approved by shareholders:

 

 

Total votes for

% of shares voted

Total votes against

% of shares voted

Total votes

Votes withheld

Ordinary resolutions

 

 

 

 

 

 

Resolution 1: To receive and adopt the report of the directors and the audited accounts of the Company for the period ended 31 December 2023

91,444,802

99.94

55,722

0.06

91,500,524

-

Resolution 2: To re-elect Simon Neicheril as a director of the Company

91,426,718

99.94

54,753

0.06

91,481,471

19,053

Resolution 3: To re-elect Robert Fary as a director of the Company

91,426,718

99.94

54,753

0.06

91,481,471

19,053

Resolution 4: To re-elect Paul Tuson as a director of the Company

91,426,574

99.94

54,897

0.06

91,481,471

19,053

Resolution 5: To re-appoint Gerald Edelman LLP as auditor to the Company

91,456,503

99.95

43,877

0.05

91,500,380

144

Resolution 6: To authorise the directors to determine the remuneration of the auditors

91,442,594

99.96

38,877

0.04

91,481,471

19,053

Resolution 7: To grant the directors authority to allot shares pursuant to Section 551 of the Companies Act 2006 and grant rights to subscribe for, or convert any security into, shares

91,439,344

99.93

61,180

0.07

91,500,524

-

Special resolutions







Resolution 8: To dis-apply pre-emption rights pursuant to Section 570 of the Companies Act 2006

86,818,255

94.90

4,663,216

5.10

91,481,471

19,053

Resolution 9: To authorise the directors to make market purchases

86,896,258

94.97

4,604,266

5.03

91,500,524

-

 

 

For further information please contact:

 

Belluscura plc 

Tel: +44 (0)20 3128 8100 

Adam Reynolds, Chairman 

Robert Rauker, Chief Executive Officer 

Simon Neicheril, Chief Financial Officer 




SPARK Advisory Partners Limited

(Nominated Adviser)

Tel: +44 (0)20 3368 3550 

Neil Baldwin / Jade Bayat




Dowgate Capital Limited

(Broker)

Tel: +44 (0)20 3903 7715 

James Serjeant / Russell Cook 




MHP Group

(Financial PR & Investor Relations)

Tel: +44 (0)20 3128 8100 

Katie Hunt / Matthew Taylor  

 belluscura@mhpgroup.com 

 

 

About Belluscura plc (https://belluscura.com/)

 

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEADPXAFKLEFA]]>
TwitterFacebookLinkedIn